REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026 UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025 REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending FDAFDA advisory committee meetings scheduled: late July 2026 RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026 UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025 REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending FDAFDA advisory committee meetings scheduled: late July 2026 RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Ben Greenfield

Influencer

Ben Greenfield

About

Ben Greenfield (born December 20, 1981) is a triathlete, personal trainer, nutritionist, author, public speaker, and former bodybuilder known for the practice of biohacking. He has participated in 13 Ironman competitions and over 120 races, becoming a USA Triathlon top-ranked athlete in his age group for a period of time.

Videos

The 4 Hidden Reasons You Can't Lose Weight.

BEDRIDDEN AT 26: How Food Reversed Her Autoimmune Disease

The 4 Hidden Reasons You Can't Lose Weight.

Why Your Wounds Take So Long to Heal (And What Actually Fixes It)

Microplastics, Seed Oils, Bad Posture & Why You're Still Sick Despite Doing Everything Right

Mark Sisson: Forget VO2 Max — This Is What Peak Health Actually Looks Like at 72

Why "Healthy" People Are Toxic: EMFs, Body Burden & the Detox Protocol That Actually Works

I Tested Every Sleep Hack on the Planet — Here's What Actually Works

Most people are wrong about how little sleep they can get away with

The Smarter Way To Build Muscle (Backed By Science)